Page last updated: 2024-08-25

zoledronic acid and sb 203580

zoledronic acid has been researched along with sb 203580 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bruzzese, F; Budillon, A; Capone, F; Caraglia, M; Carbone, C; Costantini, S; Di Gennaro, E; Leone, A; Milone, MR; Piro, G; Pucci, B	1

Other Studies

1 other study(ies) available for zoledronic acid and sb 203580

Article	Year
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell death & disease, 2013, May-23, Volume: 4 Topics: Antineoplastic Agents; Cell Movement; Diphosphonates; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Exotoxins; Humans; Imidazoles; Interleukin-12; Male; p38 Mitogen-Activated Protein Kinases; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Vascular Endothelial Growth Factor A; Zoledronic Acid	2013

Article

Year

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Cell death & disease, 2013, May-23, Volume: 4

Topics: Antineoplastic Agents; Cell Movement; Diphosphonates; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Exotoxins; Humans; Imidazoles; Interleukin-12; Male; p38 Mitogen-Activated Protein Kinases; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Vascular Endothelial Growth Factor A; Zoledronic Acid

2013